Dose delay for grade 2 irAE

Vantrexa · Metastatic NSCLC

MI-2026-0013RoutineClosedWithin SLARegulatory

FAFatima Al-SayedMedical Information Lead

Received: 15 Apr 2026, 14:21 UTC
Channel: Email
Requestor type: HCP
Country / region / team: United Kingdom · Europe · MI Europe
Category: Dosing
Response type: Standard response
Owner: FAFatima Al-Sayed
Due: 20 Apr 2026, 14:21 UTC
Responded: 16 Apr 2026, 06:21 UTC
Quality review: Not required
Related insight: —
Related standard response: SR-VTX-004 · Dose delay for grade 2 immune-related adverse events (v2)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Current stageClosedDemo action — not persisted

Routine: 120 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

120

Elapsed

16 h

to response

Remaining

104 h

13%

15 Apr 2026, 14:21 UTC
Received via Email
HCP · United Kingdom
15 Apr 2026, 14:21 UTC
Triage and assignment
Urgency Routine · assigned to MI Europe
16 Apr 2026, 06:21 UTC
Response sent
Standard response · quality review not required
20 Apr 2026, 14:21 UTC
SLA due (120 h)

Demo — drafts are not persisted

AI suggestion available for non-safety inquiries

Draft response

Timestamp	Action	User	Field	Change	Reason	Source	Event
13 Sept 2026, 16:31 UTC	Create	Fatima Al-Sayed	topics	Draft → Submitted	—	API	AUD-002012

Data lineage: MI inquiry platform (IRMS, INT-05) · received 15 Apr 2026 · hourly sync.